About Us

Home / About Us

Our Team

Our leadership team is made up of individuals who are dedicated to upholding the company’s core principles of cutting-edge technology, quality, and integrity.

Our α-Klotho Story

Today’s biologic medicines, like antibodies and recombinant proteins, are all derived from genetic materials. The DNA (gene) known to produce a therapeutic protein is inserted into a host cell, such as a bacteria or mammalian cells.

Products

We’re dedicated to realizing the potential of protein, cell, and gene therapies to offer transformative patient outcomes in areas of high unmet medical need by extending the reach of protein, cell, and gene therapies to highly prevalent neurodegenerative disorders.
klotho neurosciences

Our Vision & Our Mission

Klotho Neurosciences is dedicated to realizing the potential of biologic, cell and gene therapies to offer transformative patient outcomes in areas of high unmet medical need by extending the reach of protein, cell, and gene therapies to highly prevalent neurodegenerative disorders like Alzheimer’s, amyotrophic lateral sclerosis (ALS), Parkinson’s, and other age-related disorders.

Our vision is to build a leading gene therapy company for the treatment of neurodegenerative diseases by progressing our patented á-Klotho gene therapy research programs and identifying, developing, and commercializing other novel gene therapy treatments and in vitro diagnostics for neurodegenerative diseases, and other age-related pathologies.

We have assembled a portfolio of gene therapy candidates in partnership with leading scientific institutions and have built a team with extensive experience in the biotechnology commercialization and gene therapy space. Our team will pursue new innovations in vector design and delivery to optimize our investigational gene therapy products for safety, potency, durability, and clinical response. We plan on building integrated internal development capabilities from product development through commercialization and focus on accelerating the pace of product development in the clinic. In addition, as part of our ongoing business strategy, we continue to explore potential opportunities to acquire or license new product candidates as well as opportunities for partnership or collaboration on our existing products in development.

Our scientific approaches are innovative and offer the promise of significant long-lasting therapeutic effects in devastating illnesses such as ALS, Alzheimer’s, and Parkinson’s.
cell & gene therapies

Platform Technologies

Our strategic development and investment efforts are primarily focused around our key technology that consists of

  • A cell therapy and gene therapy platform that uses a gene therapy approach to introduce a human gene into the body. That gene is our patent-protected secreted form of Klotho, s-KL. The s-KL gene when introduced into the body produces Klotho, a therapeutic protein to treat neurodegenerative diseases and other age-related disorders.

We have a highly experienced team managing our key cell therapy and gene therapy platform. In pursuing our mission of developing therapeutic agents based on the human á-Klotho gene, we will initially focus on the development of a treatment for amyotrophic lateral sclerosis (“ALS” or “Lou Gehrig’s Disease), followed by treatments for Alzheimer’s and Parkinson’s disease.

We believe that there is currently limited competition in our pursuit of the therapeutic potential of the human á-Klotho gene due to our strong intellectual property position and technology know-how. Thus, our portfolio of gene therapy candidates targets a broad spectrum of indications across many age-related diseases, and potentially “aging” itself.

In summary, Klotho Neurosciences was founded to develop and provide disruptive new therapies to alleviate and/or reverse the progression of neurodegenerative diseases through the use of cell and gene therapy. Our goal is to develop innovative treatments for people with amyotrophic lateral sclerosis (“ALS” or “Lou Gehrig’s Disease”), Alzheimer’s and Parkinson’s disease.

Our Pipeline

Developing Life-Extending
Cell and Gene Therapies